Oncology

Showing 15 posts of 308 posts found.

FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment

January 30, 2024
Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma

Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …

Vergent Bioscience shares phase 2 data for VGT-309

January 29, 2024
Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer

Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …

Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality

January 25, 2024
Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab

Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …

Onward Therapeutics announces enrolment of phase 1 trial of bispecific antibody

January 24, 2024
Research and Development Oncology, Onward Therapeutics, bispecific antibody, clinical trial

Onward Therapeutics has announced that it has begun enrolment for its phase 1 clinical trial of OT-A201, a novel bispecific …

InnoCare announces first patient dosed in zurletrectinib clinical trial in China

January 24, 2024
Research and Development InnoCare, Oncology, clinical trial, zurletrectinib

InnoCare Pharma has announced that the first paediatric patient has been dosed in a clinical trial of the company’s second …

FDA approves Balversa for bladder cancer treatment

January 22, 2024
Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …

Verastem Oncology gains Fast Track Designation for combination NSCLC treatment

January 19, 2024
Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology

Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …

FDA clears DermaSensor’s AI detection device for skin cancer

January 18, 2024
Medical Communications FDA, Oncology, skin cancer

DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …

Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment

January 18, 2024
Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial

Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …

Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software

January 17, 2024
Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia

Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …

FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment

January 15, 2024
Medical Communications FDA, Oncology, cervical cancer, keytruda

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

Merck to acquire Harpoon Therapeutics for approximately $680m

January 10, 2024
Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …

Fate Therapeutics initiates phase 1 trial for solid tumour treatment

January 9, 2024
Research and Development Fate Therapeutics, Oncology, solid tumours

Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …

Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery

January 4, 2024
Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology

Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

January 2, 2024
Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …

The Gateway to Local Adoption Series

Latest content